HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid

Subscribe to New Research on 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid

A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)

Also Known As:

(15S)-Hydroxy-11 alpha, 9 alpha-(epoxymethano)prosta-5Z, 13E-dienoic Acid; (15S)hydroxy-9alpha,11alpha-(epoxymethano)prosta-5,13-dienoic acid; 11 alpha,9 alpha-Epoxymethano PGH2; 9,11-Dideoxy-11 alpha,9 alpha-epoxymethanoprostaglandin F2 alpha; 9,11-Dideoxy-11 alpha,9-alpha-epoxymethano-PGF2 alpha; 9,11-epoxymethano-PGH2; U-44619; U-46619; U44619; U46619; 11 alpha,9 alpha Epoxymethano PGH2; 9,11 epoxymethano PGH2; U 44619; U 46619; 5-Heptenoic Acid, 7-(6-(3-Hydroxy-1-Ocentyl)-2-Oxabicyclo(2.2.1)hept-5-yl)-, (1R-(1alpha,4alpha,5 beta(Z),6alpha(1E,3S*)))-

Networked: 305 relevant articles (7 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Grimminger, Friedrich: 7 articles (01/2011 - 12/2003)
2.	Weissmann, Norbert: 7 articles (01/2011 - 12/2003)
3.	Seeger, Werner: 7 articles (01/2011 - 12/2003)
4.	Grimminger, F: 6 articles (08/2003 - 02/2000)
5.	Seeger, W: 6 articles (08/2003 - 02/2000)
6.	Schermuly, R T: 6 articles (08/2003 - 02/2000)
7.	Weissmann, N: 6 articles (08/2003 - 02/2000)
8.	Ghofrani, H A: 6 articles (08/2003 - 02/2000)
9.	Schermuly, Ralph T: 5 articles (01/2011 - 12/2003)
10.	Ghofrani, Hossein A: 5 articles (01/2011 - 12/2003)

Related Diseases

1.	Anoxia (Hypoxia) 10/01/1999 - "The PaO2 and HbSat were significantly improved at all NO doses during U44619 infusion but not during alveolar hypoxia. " 01/01/2015 - "To examine concurrent effects of hypoxia and thromboxane on myocyte growth, serum-fed first-passage newborn porcine PA myocytes were randomized into normoxic (21 % O2) or hypoxic (10 % O2) culture for 3 days, with daily addition of thromboxane mimetic U46619 (10(-9) to 10(-5) M) or diluent. " 12/01/2014 - "Association of Cdc42 with N-WASp decreased in hypoxia but increased after U46619 exposure. " 12/01/2014 - "Hypoxia increased phospho-PAK, unaltered by U46619. " 08/01/2012 - "Of note, U46619 also exerted a vasoconstrictive effect on two different types of postnatal PDA models: premature PDA and hypoxia-induced PDA. "
2.	Ischemia 10/01/2009 - "NS1619-induced relaxation was suppressed by ischemia (71.4 +/- 2.2% vs 95.3 +/- 1.6%; p < 0.01) and was inferior in K(+) pre-contraction, as compared with U(46619) (a thromboxane A(2) mimetic) pre-contraction (p < 0.05). " 08/01/2005 - "Compared with preischemic responses, contractile response to U46619 was depressed at all concentrations after ischemia in the OVX group. " 02/21/2005 - "In contrast, the vasoconstriction induced by U46619 remained unmodified by short ischemias but was reduced after longer periods of ischemia (30 and 45 min). " 10/01/1997 - "We have previously shown that a short period (15 min) of global ischemia in the isolated rat heart causes impaired coronary constriction in response to a thromboxane analog U46619 during reperfusion. " 01/01/1990 - "A low concentration (30 nM) of U-46619 which did not produce significant hemodynamic responses prior to ischemia caused significant decreases in isovolumic left ventricular developed pressure and increases in coronary vascular resistance during reperfusion of control but not acute or chronic diabetic hearts. "
3.	Body Weight (Weight, Body) 01/01/1991 - "Despite an initial lower systemic vascular resistance in tolerant rats compared to control rats (2.4 +/- 0.3 vs 3.1 +/- 0.2 mm Hg/ml/min/100 g of body weight, respectively, p less than 0.05), the maximum pressor response to U46619 was significantly greater (p less than 0.05) at the higher doses of U46619 in tolerant rats compared to control rats. " 08/01/2012 - "Furthermore, we found that U46619 at lower concentrations (up to 0.05 mg/g of body weight) had a minimal vasoconstrictive effect on other vessels and did not induce microthrombosis in the pulmonary capillary arteries. " 11/06/2006 - "Hemorrhage was performed by withdrawing a total volume of 2.1 ml of blood per 100 g body weight over a period of 10 min. Intracerebroventricular (i.c.v.) injection of U-46619 (0.5, 1, 2 micro g) produced a dose- and time-dependent increase in arterial pressure and reversed the hypotension of this condition. " 10/01/1993 - "An intravenous injection of U-46619 (10 micrograms) to each of eight NP chronically instrumented rabbits (mean body weight 3.4 kg) induced an immediate (1 min) and reversible fall of cardiac output (CO, 66%) and mean arterial pressure (MAP, 41%, both P < 0.01). " 10/01/1999 - "Infusion of U46619 (0.35 +/- 0.04 microg/kg of body weight/min) or alveolar hypoxia resulted in increased P(PA) and decreased arterial oxygenation (PaO2) and hemoglobin saturation (HbSat). "
4.	Rhinitis 09/01/2006 - "We evaluated the roles of nasal mucosal vascular changes following intranasal instillation of the TXA2 analog U-46619 or leukotriene (LT)D4 to induce nasal blockage in a guinea pig model of allergic rhinitis. " 01/01/2001 - "In addition, exposure of the nasal cavity of nonsensitized guinea pigs to aerosolized U-46619 or histamine also resulted in nasal plasma exudation, and S-1452 (1 mg/kg, p.o.) almost completely suppressed the U-46619-induced response but did not affect the histamine-induced one, even at a high dose of 30 mg/kg. These results indicate that TxA(2) as well as histamine may play an important role in antigen-induced nasal plasma exudation in guinea pigs, and S-1452 can be expected to be useful for the treatment of allergic rhinitis."
5.	Myocardial Ischemia (Ischemic Heart Diseases) 12/01/2008 - "BM 13,177 (30 mg/kg iv), a selective TP receptor antagonist, eliminated the reflex responses to U-46619 and significantly attenuated the excitatory responses during brief (5 min) regional myocardial ischemia. "

Related Drugs and Biologics

1.	Histamine (Histamine Dihydrochloride)
2.	Thromboxane Receptors (Thromboxane Receptor)
3.	Acetylcholine (Acetylcholine Chloride)
4.	sulotroban
5.	S 145
6.	Creatine Kinase (Creatine Phosphokinase)
7.	Antigens
8.	Ethanol (Ethyl Alcohol)
9.	Thromboxane A2 (A2, Thromboxane)
10.	tebufenozide (Mimic)

Related Therapies and Procedures

1.	Intravenous Injections
2.	Injections
3.	Catheters
4.	Microspheres (Microsphere)
5.	Intravenous Infusions